nelfinavir has been researched along with Chronic Illness in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, FT; Jensen-Fangel, S; Justesen, US; Obel, N; Pedersen, C | 1 |
| Arnaud, A; Mauboussin, JM; Peyrière, H; Rouanet, I; Vincent, D | 1 |
| Chaisson, RE; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL | 1 |
| Brown, AJ; Clotet, B; Frost, SD; Martinez-Picado, J; Parkin, NT; Petropoulos, CJ; Ruiz, L; Wrin, T | 1 |
| Bart, PA; Chapuis, AG; Lazzarin, A; Pantaleo, G; Rizzardi, GP; Tambussi, G | 1 |
| Moore, T; Ware, AJ | 1 |
2 trial(s) available for nelfinavir and Chronic Illness
| Article | Year |
|---|---|
The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Calcium Carbonate; Calcium Gluconate; Chronic Disease; Diarrhea; Drug Combinations; Drug Interactions; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Pilot Projects; Prospective Studies; Severity of Illness Index | 2003 |
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Topics: Adult; Anti-HIV Agents; Antigens, Fungal; Antigens, Viral; Antiretroviral Therapy, Highly Active; Candida albicans; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Cytomegalovirus; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Simplexvirus; Sulfonamides; T-Lymphocyte Subsets | 2000 |
4 other study(ies) available for nelfinavir and Chronic Illness
| Article | Year |
|---|---|
Chronic cough induced by abacavir apart from a context of hypersensitivity.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chronic Disease; Cough; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Middle Aged; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Rhinitis; Sputum; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination | 2002 |
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Liver; Lopinavir; Male; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Saquinavir; Treatment Outcome | 2004 |
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Topics: Carbamates; Chronic Disease; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Nelfinavir; Retrospective Studies; Sulfonamides; Virus Replication; Withholding Treatment | 2005 |
Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chronic Disease; Didanosine; Female; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Parvoviridae Infections; Parvovirus B19, Human; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |